The epidemiology of drug recalls in the United States

Archives of Internal Medicine

Volumn 172, Issue 14, 2012, Pages 1109-1110

  Wang, Bo ^a   Gagne, Joshua J ^a   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG RECALL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; MEDICAL INFORMATION; PRIORITY JOURNAL; UNITED STATES;

DRUG RECALLS; HUMANS; INFORMATION DISSEMINATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84864417983     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.2013     Document Type: Article

References (8)

1. US Food and Drug Administration. Recalls, Market Withdrawals & Safety Alerts. http://www.fda.gov/Safety/Recalls/ucm289770.htm?source=govdelivery/. Accessed February 14, 2012.
2. US Food and Drug Administration. Enforcement Reports. http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm. Accessed August 2, 2011.
3. US Food and Drug Administration. Background and definitions. http://www.fda.gov/Safety/Recalls/ucm165546.htm. Accessed August 3, 2011.
4. US Food and Drug Administration. Archive for Recalls: Market Withdrawals & Safety Alerts. http://www.fda.gov/Safety/Recalls/ArchiveRecalls/default. htm. Accessed August 2, 2011.
5. US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. http://www.fda.gov/Safety/MedWatch/default. htm. Accessed November 5, 2011.
6. US Food and Drug Administration. Pathway to global product safety and quality. http://www.fda.gov/downloads/AboutFDA/CentersOffices/ OfficeofGlobalRegulatoryOperationsandPolicy/GlobalProductPathway/UCM262528.pdf. Accessed February 21, 2012.
7. Pew Health Group. After heparin: protecting consumers from the risks of substandard and counterfeit drugs. http://www.pewhealth.org/uploadedFiles/PHG/ Content-Level-Pages/Reports/Pew-Heparin-Final-.pdf. Accessed September 8, 2011.
8. McMahon AW, Pratt RG, Hammad TA, et al. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. Pharmacoepidemiol Drug Saf. 2010;19(9):921-933.